GlassScriptPhysician profile
Malgorzata A Gajda
NPI 1548285042
$12,854.20
in general payments reported to CMS, 2019-2025
36 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,863 · 2020: $1,411 · 2021: $3,180 · 2022: $2,190 · 2023: $1,516 · 2024: $1,342 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,882.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,296.28 | 2021 | |
| Pfizer INC. | $1,242.08 | 2019-2025 | |
| Abbvie INC. | $1,100.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $998.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $982.27 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $946.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $714.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $619.18 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $469.72 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $288.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $277.58 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $272.67 | 2021-2023 | |
| Madrigal Pharmaceuticals | $216.66 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $210.77 | 2022-2025 | Veozah |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malgorzata Gajda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.